Capricor Therapeutics Inc.

04/24/2024 | Press release | Distributed by Public on 04/24/2024 07:07

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy